Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328936 | 0.93 | TP53 (0.44) | TP53ALDH1A1MAPTGAAL3MBTL1 | |
| SCHEMBL13249802 | 0.88 | KDR (0.45) | TP53ALDH1A1MAPTGAAPTGDR2 | |
| SCHEMBL13249786 | 0.88 | TSHR (0.45) | TP53ALDH1A1MAPTGAALMNA | |
| SCHEMBL13249923 | 0.86 | P2RX7 (0.41) | TP53ALDH1A1MAPTP2RX7PTGDR2 | |
| SCHEMBL13249808 | 0.85 | TP53 (0.39) | TP53ALDH1A1MAPTGAAP2RX7 | |
| SCHEMBL13249798 | 0.84 | PPARG (0.41) | TP53ALDH1A1MAPTGAALMNA | |
| SCHEMBL13249789 | 0.84 | PPARG (0.42) | TP53ALDH1A1GAAPTGDR2LMNA | |
| SCHEMBL13249799 | 0.84 | TP53 (0.40) | TP53ALDH1A1GAAL3MBTL1PTGDR2 | |
| SCHEMBL13249793 | 0.84 | TP53 (0.38) | TP53ALDH1A1GAAPTGDR2LMNA | |
| SCHEMBL13249792 | 0.84 | PPARG (0.40) | TP53ALDH1A1MAPTGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | TP53 4768/4885ALDH1A1 973/4885MAPT 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.